These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 23916847)

  • 1. Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease.
    Murphy SK; Yang H; Moylan CA; Pang H; Dellinger A; Abdelmalek MF; Garrett ME; Ashley-Koch A; Suzuki A; Tillmann HL; Hauser MA; Diehl AM
    Gastroenterology; 2013 Nov; 145(5):1076-87. PubMed ID: 23916847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease.
    Moylan CA; Pang H; Dellinger A; Suzuki A; Garrett ME; Guy CD; Murphy SK; Ashley-Koch AE; Choi SS; Michelotti GA; Hampton DD; Chen Y; Tillmann HL; Hauser MA; Abdelmalek MF; Diehl AM
    Hepatology; 2014 Feb; 59(2):471-82. PubMed ID: 23913408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted-bisulfite sequence analysis of the methylation of CpG islands in genes encoding PNPLA3, SAMM50, and PARVB of patients with non-alcoholic fatty liver disease.
    Kitamoto T; Kitamoto A; Ogawa Y; Honda Y; Imajo K; Saito S; Yoneda M; Nakamura T; Nakajima A; Hotta K
    J Hepatol; 2015 Aug; 63(2):494-502. PubMed ID: 25776890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentially methylated loci in NAFLD cirrhosis are associated with key signaling pathways.
    Gerhard GS; Malenica I; Llaci L; Chu X; Petrick AT; Still CD; DiStefano JK
    Clin Epigenetics; 2018 Jul; 10(1):93. PubMed ID: 30005700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis.
    Alonso C; Fernández-Ramos D; Varela-Rey M; Martínez-Arranz I; Navasa N; Van Liempd SM; Lavín Trueba JL; Mayo R; Ilisso CP; de Juan VG; Iruarrizaga-Lejarreta M; delaCruz-Villar L; Mincholé I; Robinson A; Crespo J; Martín-Duce A; Romero-Gómez M; Sann H; Platon J; Van Eyk J; Aspichueta P; Noureddin M; Falcón-Pérez JM; Anguita J; Aransay AM; Martínez-Chantar ML; Lu SC; Mato JM
    Gastroenterology; 2017 May; 152(6):1449-1461.e7. PubMed ID: 28132890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered DNA Methylation Sites in Peripheral Blood Leukocytes from Patients with Simple Steatosis and Nonalcoholic Steatohepatitis (NASH).
    Wu J; Zhang R; Shen F; Yang R; Zhou D; Cao H; Chen G; Pan Q; Fan J
    Med Sci Monit; 2018 Oct; 24():6946-6967. PubMed ID: 30270343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease.
    Pirola CJ; Gianotti TF; Burgueño AL; Rey-Funes M; Loidl CF; Mallardi P; Martino JS; Castaño GO; Sookoian S
    Gut; 2013 Sep; 62(9):1356-63. PubMed ID: 22879518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity.
    Di Mauro S; Scamporrino A; Petta S; Urbano F; Filippello A; Ragusa M; Di Martino MT; Scionti F; Grimaudo S; Pipitone RM; Privitera G; Di Pino A; Scicali R; Valenti L; Dongiovanni P; Fracanzani A; Rabuazzo AM; Craxì A; Purrello M; Purrello F; Piro S
    Liver Int; 2019 Sep; 39(9):1742-1754. PubMed ID: 31169972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of Serum Test for Advanced Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis.
    Loomba R; Jain A; Diehl AM; Guy CD; Portenier D; Sudan R; Singh S; Faulkner C; Richards L; Hester KD; Okada L; Li XJ; Mimms L; Abdelmalek MF
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1867-1876.e3. PubMed ID: 30448594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NAFLD: Profiling NAFLD--liver gene expression and DNA methylation patterns to characterize disease severity.
    Ray K
    Nat Rev Gastroenterol Hepatol; 2013 Oct; 10(10):565. PubMed ID: 23958603
    [No Abstract]   [Full Text] [Related]  

  • 11. Identification of the genomic region under epigenetic regulation during non-alcoholic fatty liver disease progression.
    Hotta K; Kitamoto T; Kitamoto A; Ogawa Y; Honda Y; Kessoku T; Yoneda M; Imajo K; Tomeno W; Saito S; Nakajima A
    Hepatol Res; 2018 Feb; 48(3):E320-E334. PubMed ID: 29059699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Gene Expression Patterns Between Mouse Models of Nonalcoholic Fatty Liver Disease and Liver Tissues From Patients.
    Teufel A; Itzel T; Erhart W; Brosch M; Wang XY; Kim YO; von Schönfels W; Herrmann A; Brückner S; Stickel F; Dufour JF; Chavakis T; Hellerbrand C; Spang R; Maass T; Becker T; Schreiber S; Schafmayer C; Schuppan D; Hampe J
    Gastroenterology; 2016 Sep; 151(3):513-525.e0. PubMed ID: 27318147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-wide analysis of DNA methylation in human peripheral leukocytes identifies potential biomarkers of nonalcoholic fatty liver disease.
    Zhang RN; Pan Q; Zheng RD; Mi YQ; Shen F; Zhou D; Chen GY; Zhu CY; Fan JG
    Int J Mol Med; 2018 Jul; 42(1):443-452. PubMed ID: 29568887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dysregulated Hepatic Methionine Metabolism Drives Homocysteine Elevation in Diet-Induced Nonalcoholic Fatty Liver Disease.
    Pacana T; Cazanave S; Verdianelli A; Patel V; Min HK; Mirshahi F; Quinlivan E; Sanyal AJ
    PLoS One; 2015; 10(8):e0136822. PubMed ID: 26322888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic steatohepatitis is associated with a state of betaine-insufficiency.
    Sookoian S; Puri P; Castaño GO; Scian R; Mirshahi F; Sanyal AJ; Pirola CJ
    Liver Int; 2017 Apr; 37(4):611-619. PubMed ID: 27614103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A targeted analysis reveals relevant shifts in the methylation and transcription of genes responsible for bile acid homeostasis and drug metabolism in non-alcoholic fatty liver disease.
    Schiöth HB; Boström A; Murphy SK; Erhart W; Hampe J; Moylan C; Mwinyi J
    BMC Genomics; 2016 Jun; 17():462. PubMed ID: 27301979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA Methylation in Nonalcoholic Fatty Liver Disease.
    Hyun J; Jung Y
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33143364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of differentially methylated region (DMR) networks associated with progression of nonalcoholic fatty liver disease.
    Hotta K; Kitamoto A; Kitamoto T; Ogawa Y; Honda Y; Kessoku T; Yoneda M; Imajo K; Tomeno W; Saito S; Nakajima A
    Sci Rep; 2018 Sep; 8(1):13567. PubMed ID: 30206277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease.
    Hardy T; Zeybel M; Day CP; Dipper C; Masson S; McPherson S; Henderson E; Tiniakos D; White S; French J; Mann DA; Anstee QM; Mann J
    Gut; 2017 Jul; 66(7):1321-1328. PubMed ID: 27002005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Branched chain amino acid transaminase 1 (BCAT1) is overexpressed and hypomethylated in patients with non-alcoholic fatty liver disease who experience adverse clinical events: A pilot study.
    Wegermann K; Henao R; Diehl AM; Murphy SK; Abdelmalek MF; Moylan CA
    PLoS One; 2018; 13(9):e0204308. PubMed ID: 30265706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.